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afety of Transvenous Cardiac
esynchronization System Implantation
n Patients With Chronic Heart Failure
ombined Results of Over 2,000
atients From a Multicenter Study Program
ngel R. León, MD,* William T. Abraham, MD,†‡ Anne B. Curtis, MD,§ James P. Daubert, MD,
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usan Petersen-Stejskal, BS,†† Kevin Wheelan, MD,‡‡ for the MIRACLE Study Program
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vanston, Illinois; Rochester, Minnesota; Minneapolis, Minnesota; and Dallas, Texas
OBJECTIVES The purpose of this study was to evaluate the safety of implanting a cardiac resynchronization
therapy (CRT) system.
BACKGROUND Clinicians and patients require data on the safety of the CRT implant procedure to estimate
procedural risk.
METHODS We evaluated outcomes of transvenous CRT system implantation in 2,078 patients from the
Multicenter InSync Randomized Clinical Evaluation (MIRACLE) study, the MIRACLE
Implantable Cardioverter-Defibrillator (ICD) study, and the InSync III study. We compared
the MIRACLE study to the InSync III study and the MIRACLE ICD study randomized
phase to its general phase to evaluate the effect of new technologies.
RESULTS The implant attempt succeeded in 1,903 of 2,078 (91.6%) patients. Implant time decreased
from 2.7 h in the MIRACLE study to 2.3 h in the InSync III study (p  0.001), and from
2.8 h in the MIRACLE ICD study randomized phase to 2.4 h in the general phase (p 
0.001). The implant procedure produced 62 perioperative complications in 53 (9.3%)
MIRACLE trial patients; 159 in 135 (21.1%) MIRACLE ICD study randomized phase
patients and 71 in 62 (13.9%) general phase patients (p  0.05 vs. randomized); and 41 in
37 (8.8%) InSync III study patients (p  NS vs. the MIRACLE study). We observed 73
postoperative complications in 62 (11.7%) MIRACLE trial patients, 77 in 68 (11.9%)
MIRACLE ICD study randomized phase patients and 56 in 45 (11.0%) general phase
patients (p  NS), and 37 in 34 (8.6%) InSync III study patients (p  NS). A total of 8%
of patients required reoperation to treat lead dislodgement, extracardiac stimulation, or
infection during follow-up.
CONCLUSIONS Transvenous CRT system implantation appears safe, well-tolerated, has a high success rate,
and improves with operator experience and the addition of new technologies. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.031Cardiol 2005;46:2348–56) © 2005 by the American College of Cardiology Foundation
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bardiac resynchronization therapy (CRT) provides effective
djunctive therapy for patients with symptomatic heart
ailure and a wide QRS complex who remain symptomatic
ptimal pharmacological therapy. However, few large scale
tudies analyze the safety of implanting a CRT system in
uch chronically ill individuals.
Cardiac resynchronization therapy device implant origi-
ally combined a surgical approach to direct left ventricular
LV) lead placement with transvenous insertion of the right
From the *Carlyle Fraser Heart Center/Division of Cardiology, Emory University,
tlanta, Georgia; †University of Kentucky, Lexington, Kentucky; ‡The Ohio State
niversity Heart Center, Columbus, Ohio; §University of Florida, Gainesville,
lorida; University of Rochester Medical Center, Rochester, New York; ¶North-
estern University, Evanston, Illinois; #The Mayo Clinic, Rochester, Minnesota;
*Harper Hospital, Detroit, Michigan; ††Medtronic, Inc., Minneapolis, Minnesota;
nd ‡‡Baylor University Medical Center, Dallas, Texas. This study was supported by
edtronic, Inc., Minneapolis, Minnesota.a
Manuscript received November 24, 2004; revised manuscript received March 1,
005, accepted March 10, 2005.trial (RA) and right ventricular (RV) pacing leads (1,2).
he surgical approach, requiring general anesthesia and
horacotomy, assured successful LV lead implantation but
lso introduced increased morbidity and mortality (3). The
ubsequent introduction of a fully transvenous approach to
RT provided a potentially safer alternative to surgical LV
picardial lead placement (1,4). Early transvenous CRT
mplants utilized standard RV leads adapted to LV pacing
ntil the development of specialized LV leads and delivery
ystems provided dedicated leads for CRT. The safety and
fficacy of implanting a transvenous CRT system using
hese leads and delivery systems remains largely unknown,
s most published clinical trials to date have provided
imited data to adequately assess their use.
Given the potentially large number of patients who might
enefit from CRT, patients and clinicians should have
ccess to ample data on the safety and efficacy of the implant
p
r
s
i
l
M
d
M
s
o
e
o
t
a
s
s
s
g
a
M
D
e
s
s
u
p
s
M
c
h
m
r

c
o
c
w
i
s
(
n
r
M
p
r
N
c
C
u
I
i
t
i
m
C
T
d
c
i
p
T
A
G
E
N
Q
L
L
H
D
A
B
A
d
D
2349JACC Vol. 46, No. 12, 2005 León et al.
December 20, 2005:2348–56 Safety of Biventicular Pacingrocedure to create reasonable expectations of procedural
isk. To better understand these risks, we evaluated the
uccess and complication rates for transvenous CRT system
mplantation in over 2,000 patients from three completed
arge clinical studies of CRT (collectively referred to as the
IRACLE study program): the Multicenter InSync RAn-
omized CLinical Evaluation (MIRACLE) study, the
IRACLE Implantable Cardioverter-Defibrillator (ICD)
tudy, and the InSync III study. Here we report the
utcomes of the implant procedure, including the safety and
ffectiveness of the implant technique, and the performance
f the components of the biventricular pacing system from
he time of implant through the six-month follow-up. We
lso looked for a learning curve within the MIRACLE
tudy, and compared implant success in the MIRACLE
tudy to the InSync III study and in the MIRACLE ICD
tudy randomized phase to the MIRACLE ICD study
eneral phase to evaluate the effect of operator experience
nd new technologies on implant efficacy.
ETHODS
esign. The rationale, design, and primary heart failure
fficacy results of the MIRACLE and MIRACLE ICD
tudies appear in print elsewhere (5,6). The InSync III
tudy, a prospective, multicenter, nonrandomized trial, eval-
ated the safety and efficacy of sequential biventricular
able 1. Baseline Demographics
Parameters
MIRACLE
n  571
ge, yrs (mean  SD) 64  11
ender, % male 68
thnicity, % Caucasian 90
YHA, % functional class III 90
RS, ms (mean  SD) 166  21
V ejection fraction, % 22  6
VEDD, mm (mean  SD) 69  10
F etiology, % ischemic 55
iuretic use, % 94
CE-I or ARB use, % 92
eta-blocker use, % 55
CE-I  angiotensin-converting enzyme inhibitor; ARB  aldosterone receptor blo
Abbreviations and Acronyms
AERC  Adverse Events Review Committee
CRT  cardiac resynchronization therapy
CS  coronary sinus
ICD  implantable cardioverter-defibrillator
LV  left ventricle/ventricular
MIRACLE  Multicenter InSync Randomized Clinical
Evaluation
NYHA  New York Heart Association
RA  right atrial/atrium
RV  right ventricle/ventricular
SCD  sudden cardiac deathiameter; Miracle  Multicenter InSync Randomized Clinical Evaluation; Miracle ICD
efibrillator; NYHA  New York Heart Association.acing. The InSync III study patients received an InSync III
ystem with active CRT. The InSync III study used the
IRACLE study “off” (control) group as the control for
omparing the efficacy of the InSync III system (7).
Patients in all three studies underwent testing after
ospital discharge and at one month, three months, six
onths, and every six months thereafter. Each study en-
olled patients with LV dysfunction (LV ejection fraction
35%), New York Heart Association (NYHA) functional
lass III or IV heart failure despite use of a stable and
ptimal heart failure drug regimen, and ventricular dyssyn-
hrony defined by a QRS duration 130 ms. Patients gave
ritten informed consent under guidelines approved by the
nstitutional review board of each participating center.
Patients enrolled in the MIRACLE and InSync III
tudies underwent implantation of a CRT pacing device
InSync or InSync III, Medtronic Inc., Minneapolis, Min-
esota); those enrolled in the MIRACLE ICD study
eceived a combined CRT-ICD system (InSync ICD,
edtronic Inc.). The MIRACLE ICD study enrolled
atients with a standard ICD indication in two phases: a
andomized placebo-controlled phase, which included
YHA functional class II patients, and a general phase that
ontinued the safety evaluation with all patients receiving
RT. The general phase included the additional optional
se of the Model 4193 over-the-wire LV lead (Medtronic
nc.). The three studies excluded patients who met standard
ndications for pacing.
All patients without a preexisting device underwent a
ransvenous insertion of RA, RV, and LV electrodes and
mplantation of a CRT. Patients with an existing ICD who
et MIRACLE CRT indications underwent an upgrade to
RT-ICD using, when possible, the existing right heart leads.
he studies utilized various left-heart leads and left-heart
elivery systems (Table 1). The three CRT systems used
onventional commercially available RA and RV electrodes.
The defined perioperative period included the day of
mplant plus the seven subsequent days. The postoperative
eriod included day eight through six months. The prede-
IRACLE ICD
n  1,085
InSync III
n  422
Total
n  2,078
66  11 66  11 66  11
78 58 72
NA 86 88
61 92 75
166  23 164  22 166  22
21  7 21  7 22  7
70  10 69  10 70  10
64 47 58
91 92 92
92 90 92
64 69 63
HF  heart failure; LV  left ventricular; LVEDD  left ventricular end-diastolicM
cker;
 Multicenter InSync Randomized Clinical Evaluation Implantable Cardioverter
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Safety of Biventicular Pacing December 20, 2005:2348–56ermined definition of a complication included any event
equiring intravenous fluid or medication administration or
ny invasive intervention.
mplant procedure. The procedure took place in either a
ardiac electrophysiology laboratory, cardiac catheterization
aboratory, or operating suite. Implanter training included
he presence of an experienced implanter at each newly
stablished investigational center to mentor the center’s first
mplant. Conscious sedation with local anesthesia or general
nesthesia provided patient comfort and analgesia. The
mplant began with the establishment of central venous
ccess by subclavian vein puncture and/or cephalic vein cut
own for insertion of RA and RV leads and the LV lead
elivery system. Commercially available pacing lead intro-
ucers facilitated access into the venous circulation. The
mplanters used standard stylet-driven insertion technique
o place the atrial lead in the right appendage, free wall, or
eptal locations depending on operator preference. The
tudy designs encouraged placement of RV leads at the
pex, but also accepted a septal location. Transvenous
lacement of the LV lead required cannulation of the
oronary sinus (CS) with a specialized delivery system
onsisting of a straight or preshaped CS guide catheter, a
exible guidewire, and a hemostasis valve. In cases where
he guide catheter alone failed to enter the CS, cannulation
f the CS by a deflectable electrophysiologic mapping
atheter or preshaped angiographic catheter inserted
hrough the guide catheter provided access into the CS. The
rotocol required contrast venography of the CS to delin-
ate the cardiac venous anatomy and identify potential
igure 1. (A) Left anterior oblique view of balloon occlusive contrast inj
nterventricular, and lateral left ventricular (LV) veins. The right ventricular
blique view demonstrating separation between the RV lead at the septalarget veins for LV lead insertion (Fig. 1A). The implanter melected the target vein based on the visualized anatomy.
cquisition and storage of venogram images in multiple
uoroscopic projections provided a reference of venous
natomy to guide the LV lead insertion procedure. The
nterior-lateral, lateral, or posterior-lateral veins served as
rimary targets in order to maximize RV and LV electrode
eparation (Fig. 1B). Implanters selected secondary targets
nly when venous anatomy, stimulation threshold, stability,
r extracardiac (diaphragmatic) stimulation prevented lead
elivery to the primary site. The implanting physician
esignated the location of the LV tip electrode to be
ecorded at the time of implantation. Each study provided
wo or three LV lead options (Table 1). When successful
elivery of the LV electrode produced acceptable stimula-
ion thresholds (3.0 V) in the absence of extracardiac
timulation, removal of the lead delivery system preceded
he determination of final electrical implant parameters.
he inability to deliver an LV lead into any venous branch
efined a failed implant attempt.
A pacing system analyzer (Medtronic Analyzer model
090, Medtronic Inc.) measured the capture thresholds,
-wave and P-wave amplitudes, and pacing impedance
uring overdrive pacing through the RA, RV, and LV
lectrodes. Successful LV lead implantation led to connec-
ion of the three electrodes to the CRT device. A final
nterrogation of the implanted system at the time of hospital
ischarge confirmed satisfactory capture thresholds for each
lectrode. The follow-up scheme included comprehensive
evice interrogation to assess lead performance at one,
hree, and six months for all patients regardless of assign-
of the coronary sinus demonstrating the anterior descending, posterior
pacing lead appears fixed at the mid-right septal surface. (B) Left anterior
on and the LV lead at the lateral position on the LV free wall.ectionent to control or CRT.
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December 20, 2005:2348–56 Safety of Biventicular PacingThe primary investigator initially classified the cause of
eath in patients who died in each study. An adverse Events
eview Committee (AERC) independently reviewed each
eath and served as the final arbiter of the cause.
The MIRACLE trial generated a learning curve by
roviding data from a center’s first implants without the
onfounding effects of participation in previous CRT trials
r experience with commercialized lead and delivery sys-
ems. The learning curve analysis compared implant success
ithin the MIRACLE study, average implant time, and
uoroscopy time as a function of center experience. The
enters appear grouped by the number of their implant
ttempts (1 to 5 attempts, 6 to 10 attempts, and 11
ttempts). A second analysis compared implant outcomes
etween chronologically sequential studies in order to de-
ermine the effect of increasing operator experience and
ntroduction of new technology on implant outcomes. That
nalysis compares total procedure duration, time to CS
annulation, and time to first acceptable lead position in the
andomized and general phases of the MIRACLE ICD
tudy, and between the MIRACLE and the InSync III
tudies.
tatistical analysis. The specific device-related electrical
ata appear as mean  SD. We calculated the implant
uccess rate as the number of successful implants divided by
he total number of patients undergoing a procedure with an
xact two-sided 95% confidence interval. The chi-square
est compared differences in the implant success rates and
he percentage of patients with complications between the
roups. The Wilcoxon rank-sum test compared the differ-
nces in the average implant and fluoroscopy times. The
aplan-Meier method calculated the probability of 30-day
ortality. All patients undergoing an attempted implant
ntered the perioperative analysis of complications; all
atients with successfully implanted devices proceeded to
ostoperative analysis of freedom from device-related (LV
ead, system) complications at six months. Values of p 
.05 denote significant differences.
ESULTS
ll together the three studies enrolled a total of 2,078
atients who underwent an attempted CRT system implant
t 98 centers throughout the U.S. and Canada with an
verage of 21 implants per center. Table 1 lists the baseline
haracteristics of this population. The MIRACLE study
nrolled patients from November 1998 to December 2000,
he MIRACLE ICD study randomized phase from Octo-
er 1999 to August 2001, the MIRACLE ICD study
eneral phase from August 2001 through June 2002, and
he InSync III study from November 2000 to June 2002.
mplant success. The CRT device implant procedure suc-
eeded in 1,903 of 2,078 (91.6%) patients, with 35 (1.8%)
equiring more than one attempt to achieve success. The
easons most commonly cited for unsuccessful implants
nclude inability to access the CS ostium (n  69), acute pislodgement or unstable lead position (n 59), or inability
o obtain a distal lead position (n  52). The available final
V lead position in 1,859 (98%) of the patients include 794
42.7%) in the lateral vein, 547 (29.4%) in the posterior-
ateral, 110 (5.9%) in the posterior, 253 (13.6%) in the
nterior, 92 (5.0%) in the anterior-lateral, and 63 (3.4%) in
he middle cardiac vein. The LV lead utilized in successful
mplants included the stylet-driven model 2187 lead in 676
35.5%) patients, the stylet-driven model 4189 in 475
25.0%) patients, the over-the-wire model 4193 (Medtronic
nc.) in 722 (37.9%) patients, and the stylet-driven model
188 in 27 (1.4%) patients. A successful implant attempt
ould have used more than one lead. The implant success
ates (95% confidence interval) for each of the studies were:
he MIRACLE study, 92.5% (90.0 to 94.5); MIRACLE
CD study randomized phase, 89.2% (86.5 to 91.5);
IRACLE ICD study general phase, 91.5% (88.5 to 94.0);
nd the InSync III study, 94.1% (91.4 to 96.1).
The MIRACLE ICD study included 357 patients with
re-existing ICD devices for upgrade to CRT-ICD. The
pgrade procedure succeeded in 320 patients (89.6%).
The MIRACLE study implant success rate for the first 5
mplant attempts at each center averaged 89.6% (84.2 to
3.6), increasing to 94.6% (89.2 to 97.8) for the second 5
mplant attempts, and continuing at 93.4% (89.7 to 96.1)
or all implant attempts after the 10th. Compared with the
rst five attempts per center, total procedure time decreased
ignificantly with increased experience as shown in Figure 2.
The overall median implant time in the MIRACLE
tudy program measured 2.6 h. The median implant dura-
ion (25th, 75th interquartiles) in the MIRACLE study
easured 2.7 (2.1, 3.6) h; 2.8 (2.2, 3.7) h in the MIRACLE
CD study randomized phase; 2.4 (1.8, 3.1) h in the
IRACLE ICD study general phase; and 2.3 (1.8, 3.0) h
n the InSync III study. Implant time decreased significantly
n the InSync III study (p  0.0001) compared to the
IRACLE study, and in the MIRACLE ICD study
eneral phase to the randomized phase (p  0.0001).
Median time to CS cannulation decreased from 11.0 (5.0,
2.0) min in the MIRACLE study to 6.5 (3.0, 15.0) min in
he InSync III study (p  0.001) and from 8.0 (4.0, 15.0)
in in the MIRACLE ICD study randomized phase to 5.0
3.0, 12.0) min in the MIRACLE ICD study general phase
p  0.001). Median time to first acceptable LV lead
osition decreased from 16.0 (8.0, 40.0) min in the
IRACLE study to 10.5 (5.0, 22.0) min in the InSync III
tudy (p  0.001) and from 12.0 (6.0, 26.0) min in the
IRACLE ICD study randomized phase to 10.0 (5.0,
1.0) min in the MIRACLE ICD study general phase (p
.001). Median fluoroscopy time decreased from 33.0 (19.0,
5.0) min in the MIRACLE study to 27.6 (16.5 47.0) in
he InSync III study (p 0.05) and from 33.9 (20.4, 51.4)
in in the MIRACLE ICD study randomized phase to
8.9 (18.1, 45.5) min in the MIRACLE ICD study general
hase (p  0.005).
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Safety of Biventicular Pacing December 20, 2005:2348–56The LV lead was implanted via subclavian vein puncture
85%), axillary vein puncture (8%), or cephalic vein cut
own (7%). At implant, the mean LV lead pacing threshold
easured 1.5 V at a 0.5-ms pulse width; mean LV lead
mpedance measured 747 ohms; and the mean R-wave
mplitude sensed from the LV measured 13.5 mV. The LV
acing thresholds for the entire group changed from 1.65
.23 V before discharge to 1.73  1.17 V at the six-month
ollow-up. Figure 3 shows the LV lead pacing thresholds
rom each lead model over time. Voltage threshold values
ose early and then decreased over time. The steroid-eluting
odels 4189 and 4193 demonstrated no apparent peak
uring the immediate postimplant period and more consis-
ent threshold over time. An analysis of all acute RA lead
ata demonstrated a mean pacing threshold of 1.1 V at a
ulse width of 0.5 ms, a mean impedance of 553 ohms, and
mean P-wave amplitude of 3.2 mV. Right ventricular lead
igure 2. (A) Implant success rates with 95% confidence intervals. The
mplant success rate of 89.6% (163 of 182 in 43 centers) for a center’s first
attempts increased to 94.6% (123 of 130 in 29 centers) for a center’s next
to 10 attempts and stabilized at 93.4% (242 of 259 in 22 centers) for a
enter’s next 11 or more implant attempts (p  0.18). (B) Total implant
ime (mean  SD) from incision to closure by attempts. We observed a
tatistically significant difference among the implant times (analysis of
ariance, p  0.001). Using Dunnett’s test, comparing the first 5 implants
o the second 5 implants and to the 11 implants, the implant times differ
t an adjusted p  0.05 level.ata included a mean pacing threshold of 0.9 V at a pulse
p
Lidth of 0.4 ms, a mean impedance of 629 ohms, and mean
ensed R-wave amplitude of 14.6 mV.
mplant/system complications. Table 2 lists all lead-,
ystem-, and procedure-related perioperative complications
eparately for each study and for the total MIRACLE study
rogram. We observed a total of 333 perioperative compli-
ations in 287 patients, and 243 postoperative complications
n 209 patients.
The AERC classified a total of eight (0.3%) deaths as
rocedure-related. Two of the deaths occurred in the
IRACLE study. One patient developed progressive hy-
otension after implant and died later the same day; the
ther experienced asystole, required cardiopulmonary resus-
itation, did not recover neurologic function, and died one
onth later. Five deaths occurred during the randomized
hase of the MIRACLE ICD study: two as the result of
rogressive heart failure (one with respiratory and renal
ailure, the other with severe mitral valve disease), one from
achyarrhythmia, one from a bradyarrhythmic event, and
ne from an acute coronary syndrome. The one procedure-
elated death in the InSync III study resulted from tachy-
rrhythmias initiated during the implant.
A total of 45 patients experienced CS dissections or
erforations, cardiac perforations, or cardiac vein dissection
r perforation; 21 of the 45 (46.7%) still received a CRT
ystem during the same implant session or at a later attempt.
ight patients required intervention for presumed or con-
rmed hemopericardium: two received intravenous pressor
nfusion, four underwent pericardiocentesis, and two re-
uired both pericardiocentesis and intravenous fluid or
ressor infusion. All patients recovered without further
equelae and continued in the studies. Of the total 45 CS
raumas, seven occurred during use of the Model 2187 or
188 lead, eight with the model 4189, and two with the
odel 4193. The remaining events resulted from use of
ther implant access catheters or wires. Seventeen patients
n the MIRACLE ICD study received only a standard ICD
ystem after abandonment of the LV lead implant. Insertion
f the RA or RV leads produced five cardiac traumatic
igure 3. Voltage pacing thresholds, over time, for all four primary left
entricular (LV) leads implanted in the Multicenter InSync Randomized
linical Evaluation (MIRACLE) study program. M  month; Pre-dis 
redischarge. Diamonds  LV 2187; triangles  LV 2188; squares 
V 4193; circles  LV 4189.
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December 20, 2005:2348–56 Safety of Biventicular Pacingvents: one required pericardiocentesis and lead replace-
ent, and two resolved with lead replacement or reposi-
ioning. One RA perforation occurred when the screw of
he lead penetrated the anterior atrial wall and punctured
he aorta leading to surgical exploration and repair. Table 3
ists lead, device or system, and procedure-related postop-
rative complications.
Thirty-three patients died during the first 30 days after
mplant, yielding a 30-day mortality rate of 1.5%. The
able 2. Perioperative Complications From CRT Device Implan
Lead Model(s) Used/Primary Lead Recommended
(% Used)
MIRACLE
2,187/2,188
(97.5%)
2
Event Description†
Patients/
Events
eads total 32/35
V lead subtotal 19/21
Lead dislodgement 7/7
Elevated pacing thresholds/failure to/loss of
capture
4/4
Muscle stimulation-diaphragm 1/1
Cardiac/cardiac vein/CS perforation or dissection 4/4
Arrhythmias (AF/VT/VF/junctional)
Other 5/5
A lead subtotal 5/5
Lead dislodgement 3/3
Elevated pacing thresholds/failure to/loss of
capture
Cardiac/cardiac vein/CS perforation or dissection
Arrhythmias (AF/VT/VF/junctional) 2/2
Other
V lead subtotal 9/9
Heart block 6/6
Elevated pacing thresholds/failure to/loss of
capture
1/1
Lead dislodgement 1/1
Cardiac perforation
Other 1/1
mplant tools total 4/4
Cardiac/cardiac vein/CS perforation or dissection 2/2
Hemo/pneumothorax
Arrhythmias (AF/VT/VF/junctional)
Heart block 1/1
Other 1/1
ystem-related total 1/1
rocedure-related total 19/22
Pocket pain/seroma/hematoma/shoulder
pain/discomfort
Hypotension 3/3
Heart block 11/11
Arrhythmias (AF/VT/VF/junctional) 4/4
Heart failure decompensation
Hemo/pneumothorax 1/1
Cardiac/cardiac vein/CS perforation or dissection
Thrombosis
Other 3/3
Each complication was related to a lead, the procedure, or the system without
rocedure-related complication.
AF  atrial fibrillation; CRT  cardiac resynchronization therapy; CS  corona
entricular fibrillation; VT  ventricular tachycardia; other abbreviations as in Tablemplant procedure led to 8 deaths, 10 resulted from pro- oressive heart failure, 11 from sudden cardiac death (SCD),
nd 4 from noncardiac causes. An additional 101 patients
4.9%) died between day 31 and the 6-month follow-up,
ncluding 51 from progressive heart failure, 28 from SCD,
3 from noncardiac causes, and 9 that remained unclassified.
One hundred sixty-one (7.7%) patients required 175
ead revisions either by repositioning or replacement
uring the six-month follow-up period. The reasons for
evision included dislodgement, loss of LV capture with-
*
-ICD
domized
2,188/4,189
48.5%)
M-ICD
General
2,187/2,188/4,193
(90.4%)
InSync III
2,187/2,188/4,193
(88.9%) Total
atients/
vents
Patients/
Events
Patients/
Events
Patients
(% of
Attempts)
67/73 28/29 10/10 137 (6.6%)
54/55 22/22 5/5 100 (4.8%)
19/19 10/10 2/2
14/15 2/2
9/9 6/6 1/1
9/9 2/2 1/1
1/1
2/2 3/3 1/1
10/10 2/2 4/4 21 (1.0%)
7/7 1/1 2/2
1/1 1/1
2/2
1/1
1/1
8/8 5/5 1/1 23 (1.1%)
2/2
2/2 1/1
1/1 1/1
1/1 1/1
2/2 2/2 1/1
16/17 3/3 8/8 31 (1.5%)
10/10 3/3 7/7
1/1
1/1 1/1
1/1
3/4
10/12 1/1 12 (0.6%)
49/57 33/38 20/23 121 (5.8%)
17/20 9/9 2/2
6/6 7/7
3/3
1/1 3/3 3/3
5/5 2/2 1/1
2/2 1/1 3/3
1/1
2/2
19/21 15/15 11/11
cation. †An individual patient may have had more than one lead-, system-, or
s; M-ICD  MIRACLE ICD; RA  right atrial; RV  right ventricular; VF tation
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Safety of Biventicular Pacing December 20, 2005:2348–56timulation. An additional 20 (1.0%) patients developed
pocket infection during the six-month follow-up pe-
iod, of which 13 required explantation of the device. Of
he 13, 9 underwent successful reimplantation of a new
ystem.
The MIRACLE ICD study evaluated the InSync ICD
evice that incorporates CRT into the ICD. Thirty-two
atients in that study experienced a total of 208 shock-
eceiving episodes for reasons other than actual ventricular
achycardia or fibrillation: 14 patients received 44 shocks for
inus tachycardia, 9 received 133 shocks for atrial fibrillation
r flutter with rapid ventricular rates, 7 received 18 shocks
or supraventricular tachycardia, and 3 received 13 shocks
able 3. Postoperative Complications From Discharge Through
MIRACLE
Successfully Implanted Patients 528
Event Description†
Patients/
Events
eads total 45/54
V lead subtotal 39/45
Lead dislodgement 20/22
Muscle stimulation-diaphragm 9/9
Elevated pacing thresholds/failure to/loss of
capture
12/12
Cardiac/cardiac vein/CS perforation or dissection
Hypotension 1/1
Arrhythmias (VT/VF/AF/PMT)
Other 1/1
A lead subtotal 7/7
Lead dislodgement 7/7
Elevated pacing thresholds/failure to/loss of
capture
Other
V lead subtotal 2/2
Lead dislodgement 2/2
Muscle stimulation-diaphragm
Elevated pacing thresholds/failure to/loss of
capture
Cardiac/cardiac vein/CS perforation or dissection
Other
ystem-related total 13/13
Pocket/system infection 7/7
Thrombosis
Arrhythmias (VT/VF/AF/PMT) 2/2
Pocket pain/seroma/hematoma/shoulder pain/
discomfort
Muscle stimulation-diaphragm
Other 4/4
rocedure-related total 6/6
Pocket pain/seroma/hematoma/shoulder pain/
discomfort
Pocket/system infection
Thrombosis 2/2
Hypotension 1/1
Hemo/pneumothorax
Other 3/3
Each complication was related to a lead, the procedure, or the system without
rocedure-related complication.
PMT  pacemaker-mediated tachycardia; other abbreviations as in Tables 1 andor noise, electromagnetic interference, or oversensing. aISCUSSION
he collective MIRACLE study program represents the larg-
st reported experience of CRT system implant outcomes and
emonstrates the safety and efficacy of the transvenous LV lead
nsertion technique for providing CRT to patients with
oderate-to-severe chronic heart failure. The implant tech-
ique, the lead delivery systems, and the components of the
RT system produced a high implant success rate (91.6%) and
cceptable and stable device and LV lead electrical perfor-
ance in the large majority of patients. The LV pacing
hresholds remained stable over time.
Our predetermined definition of a complication includes
onth Follow-Up*
-ICD
domized M-ICD General Insync III Total
570 408 397 1,903
atients/
Events
Patients/
Events
Patients/
Events
Patients
(% Attempts)
49/53 35/43 22/24 151 (7.9%)
42/44 32/36 16/18 129 (6.8%)
29/30 21/23 13/14
6/6 6/6 2/2
5/5 6/6 2/2
1/1
1/1
2/2
5/5 4/4 4/4 20 (1%)
1/1 3/3 3/3
4/4
1/1 1/1
4/4 3/3 2/2 11 (0.6%)
1/1 1/1
2/2
1/1
1/1
2/2 1/1
11/11 1/1 9/9 34 (1.8%)
3/3 2/2
4/4
2/2
1/1 1/1
1/1
5/5
13/13 12/12 4/4 35 (1.8%)
4/4 5/5 1/1
6/6 2/2 1/1
1/1
1/1
2/2 4/4 2/2
cation; †An individual patient may have had more than one lead-, system-, orSix-M
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December 20, 2005:2348–56 Safety of Biventicular Pacingrom intravenous saline bolus or analgesia to cardiac surgery.
dopting this broad definition determined that procedural
omplications occurred in 496 of 2,078 (23.8%) patients
ndergoing implant attempts. The incidence of procedure-
elated deaths (8 of 2,078 or 0.4%) in patients with severe
V dysfunction and poor functional status underscores the
afety of the technique in a compromised patient popula-
ion. The observed 30-day mortality of 1.5% in this popu-
ation compares favorably with other clinical evaluations of
evice therapy in patients with heart failure and LV dys-
unction (8). Additionally, the incidence of infection, pocket
ematoma, pneumothorax, or hemothorax fell within the
urrent profile of perioperative complications of conven-
ional pacing and ICD system implantations (9,10).
Coronary sinus trauma associated with catheterization by
he guiding catheter, electrophysiology catheters, or
alloon-tipped venogram catheters represents a previously
nreported and undesirable outcome of conventional cardiac
nstrumentation and pacing lead implantation. Conceivably
outine use of venography during the LV lead implant
rocess reveals CS trauma that would have otherwise gone
nrecognized. Most cases of CS perforation or branch vein
erforation associated with guiding catheter or lead trauma
ay remain clinically silent because the low-pressure venous
ystem does not readily lead to tamponade. The adipose
issue and pericardium overlying the atrial-ventricular
roove likely encases and contains the low-pressure bleed.
e observed that intimal tears, overt dissection of the CS
nd LV vein, or CS perforation produced no clinical
equelae in most patients; 6 of 45 patients experiencing CS
rauma or cardiac perforation required pericardial drainage,
one required surgical exploration, and no patient died as a
esult. Although the clinical sequelae from CS trauma in
his series appear infrequently, the complications from
erforation or dissection still pose a potential life-
hreatening risk to these compromised patients.
Postoperative LV lead dislodgement represents a limita-
ion of transvenous CRT systems in comparison to estab-
ished RA and RV lead performance. The 5.8% lead
islodgement observed here does not differ significantly
rom those reported in other studies of CRT (11,12). The
bserved frequency of extracardiac stimulation and exit-
lock might represent additional microdislodgement of the
V lead that led to a 7.7% requirement for reoperation.
rior experience with right heart pacing leads suggests that
islodgement rates may decrease with improved technology.
islodgement rates with first generation RA leads ranged
p to 18% (13). More recent reports of RA and RV lead
islodgement rates range between 1.5% to 3.3% (9,10).
owever, the management of extracardiac stimulation and
revention of LV lead dislodgement present a continuing
hallenge to implanters and the device industry.
Combining CRT with an ICD did not introduce addi-
ional risk of arrhythmia or unnecessary shocks to patients
eceiving these devices. The occurrence of inappropriate pCD shocks in the InSync-ICD study did not differ from
hat seen in a clinical evaluation of a dual-chamber pacing-
efibrillator (14). Adding CRT to the ICD did not dem-
nstrate any increased incidence arrhythmia or create any
pparently new mechanism of proarrhythmia, nor did it
nterfere with the efficacy of ICD therapy (15).
The overall perioperative (13.8%) and postoperative
10%) complications appear greater than the complication
ates seen with conventional pacing and defibrillating de-
ices. However, the reported complication rates in the large
ingle-study experience in the Comparison of Medical
herapy, Pacing and Defibrillation in Heart Failure
COMPANION) trial agree with those we report in the
IRACLE program (16). The cumulative risk of reopera-
ion approached 9% during follow-up (lead dislodgement
nd extracardiac stimulation [7.7%] and infection [1%]).
lso, one should recognize that CS trauma, LV lead
islodgement, and extracardiac stimulation requiring repeat
peration represent three major sources of increased com-
lications inherent to CRT device implant not seen in
onventional device implantation.
The experience reported here documented the presence
f a learning curve within a study and from study to study.
mplant success increased with experience, while procedure
nd fluoroscopy time decreased for first implanters in the
IRACLE study. The initial phase of the learning curve
ppears to flatten after 10 implant attempts. Additional
mplanter experience combined with improvements in lead
elivery systems and introduction of over-the-wire lead
echnology contributed to increased implant success and
ecreased procedure time in the InSync ICD and InSync III
tudies, probably by decreasing time to CS cannulation and
V lead positioning. We observed a mixed relationship
etween complication rates and experience: implant-related
omplications (Table 2) decreased significantly from the
nitial to the latter phase of the MIRACLE ICD study, but
ot from the initial the MIRACLE study to the subsequent
nSync III study.
onclusions. The MIRACLE program experience sug-
ests that transvenous implantation of LV pacing leads
rovides an effective, well-tolerated approach to biventricu-
ar pacing and defines a risk profile to set physician and
atient expectations: the implant attempt succeeded in
pproximately 90% of patients with a 30-day all-cause
ortality of 1.5% and an additional 9% chance of needing a
econd surgical procedure for LV lead dislodgement, extra-
ardiac stimulation, or infection after an initially successful
mplant.
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